

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 70758

Title: Wilkie's syndrome as a cause of anxiety-depressive disorder: A case report and

review of the literature

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05061662

Position: Peer Reviewer

Academic degree: MD

Professional title: Research Fellow, Surgeon

Reviewer's Country/Territory: Italy

Author's Country/Territory: Romania

Manuscript submission date: 2021-08-13

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-08-13 07:37

Reviewer performed review: 2021-08-15 16:33

Review time: 2 Days and 8 Hours

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	 [] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority)[] Accept (General priority)[Y] Minor revision[] Major revision[] Pejection
Re-review	[]Yes [Y]No



7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous
statements	Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The present study descibes a case of Wilkie's syndrome associated with a secondary anxiety-depressive disorder. Additionally, A comprehensive overview of the diagnosis, treatment and characteristics of the disease is provided. The paper focuses on two main aspects: the secondary psychiatric effects and the key role of a multidisciplinary approach for disease management. This should be claim in the conclusion section of the abstract. Authors should report in the discussion if there are other studies dealing with their case. The major limitation is the short follow up period that prevents to reach conclusions on the anxiety syndrome resolution. Authors should declare it at the end of discussion. Furthermore, in the "outcome and follow up" section, they could report whether the patient has stopped or reduced the use of drugs.